Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease

Stephen P. Gray,Jay C. Jha,Kit Kennedy,Erik van Bommel,Phyllis Chew,Cedric Szyndralewiez,Rhian M. Touyz,Harald H. H. W. Schmidt,Mark E. Cooper,Karin A. M. Jandeleit-Dahm
DOI: https://doi.org/10.1007/s00125-017-4215-5
IF: 8.2
2017-02-03
Diabetologia
Abstract:Aims/hypothesisOxidative stress is a promising target in diabetes-associated vasculopathies, with inhibitors of NADPH oxidases (NOX), in particular isoforms 1 and 4, shown to be safe in early clinical development. We have explored a highly relevant late-stage intervention protocol using the clinically most advanced compound, the NOX1/4 inhibitor GKT137831, to determine whether end-organ damage can be reversed/attenuated when GKT137831 is administered in the setting of established diabetic complications.MethodsGKT137831 was administered at two doses, 30 mg kg−1 day−1 and 60 mg kg−1 day−1, to ApoE−/− mice 10 weeks after diabetes induction with streptozotocin (STZ), for a period of 10 weeks.ResultsConsistent with Nox4−/− mouse data, GKT137831 was protective in a model of diabetic nephropathy at both the 30 mg kg−1 day−1 and 60 mg kg−1 day−1 doses, through suppression of proinflammatory and profibrotic processes. Conversely, in diabetic atherosclerosis, where Nox1−/y and Nox4−/− mice have yielded qualitatively opposing results, the net effect of pharmacological NOX1/4 inhibition was protection, albeit to a lower extent and only at the lower 30 mg kg−1 day−1 dose.Conclusions/interpretationAs dose-dependent and tissue-specific effects of the dual NOX1/4 inhibitor GKT137831 were observed, it is critical to define in further studies the relative balance of inhibiting NOX4 vs NOX1 in the micro- and macrovasculature in diabetes.
endocrinology & metabolism
What problem does this paper attempt to address?